Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1177/1559325820951357 http://scihub22266oqcxt.onion/10.1177/1559325820951357 32944012!7475870!32944012     free     free     free       Dose+Response 2020 ; 18 (3): 1559325820951357 Nephropedia Template TP {{tp|p=32944012|t=2020. Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia?|pdf=|usr=}}{{32944012}} gab.com Text Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia JO: Dose Response http://www.kidney.de/pget.php?&tw=1&pmid=32944012 #FOAvip Low dose radiotherapy has been used in the pre-antibiotic era for the treatment of all kind of pneumonia, with relative success. The unimaginable daily death toll of thousands of victims dying from COVID-19 pneumonia and the marginal therapeutic value of agents tested, brings forward the re-evaluation of the position of radiotherapy in the treatment of late stage lethal COVID-induced respiratory failure. A sound biological rationale supports this idea. Immunopathology studies show that excessive inflammation and infiltration of the lung parenchyma by immune cells is the cause of death. Mice lacking IFNalphabeta receptors remain unaffected by the virus. Radiotherapy at doses of 50-200cG may exert an intense anti-inflammatory effect and reduce the burden of inflammatory cells infiltrating the lungs. Whether radiotherapy, in conjunction with remdesivir and/or macrolides can reduce the dramatic death rates related to COVID-19 is an open challenge, under the absence of an alternative solution. Twit Text FOAVip Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia ????Dose Response http://www.kidney.de/pget.php?&tw=1&pmid=32944012 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32944012 #FOAvip English Wikipedia <ref>{{Cite pmid|32944012}}</ref> Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia? #MMPMID32944012 Koukourakis MI Dose Response 2020[Jul]; 18 (3): 1559325820951357 PMID32944012show ga Low dose radiotherapy has been used in the pre-antibiotic era for the treatment of all kind of pneumonia, with relative success. The unimaginable daily death toll of thousands of victims dying from COVID-19 pneumonia and the marginal therapeutic value of agents tested, brings forward the re-evaluation of the position of radiotherapy in the treatment of late stage lethal COVID-induced respiratory failure. A sound biological rationale supports this idea. Immunopathology studies show that excessive inflammation and infiltration of the lung parenchyma by immune cells is the cause of death. Mice lacking IFNalphabeta receptors remain unaffected by the virus. Radiotherapy at doses of 50-200cG may exert an intense anti-inflammatory effect and reduce the burden of inflammatory cells infiltrating the lungs. Whether radiotherapy, in conjunction with remdesivir and/or macrolides can reduce the dramatic death rates related to COVID-19 is an open challenge, under the absence of an alternative solution. ?Low-Dose Radiotherapy for Late-Stage COVID-19 Pneumonia?(epmc).pdf DeepDyve Pubget Overpricing